Advancing gasoline desulfurization: Multi-objective fuzzy optimization in systems technology.

Ultrasonic-assisted oxidative desulfurization (UAOD) is utilized to lessen environmental problems due to sulfur emissions. The process uses immiscible polar solvents and ultrasonic waves to enhance desulfurization efficiency. Prior research focused on comparing the effectiveness of UAOD for gasoline using response surface methodology. This study evaluates the desulfurization efficiency and operating costs, including ultrasonic power, irradiation time, and oxidant amount to determine optimal conditions. The study used a multi-objective fuzzy optimization (MOFO) approach to evaluate the economic viability of UAOD for gasoline. It identified upper and lower boundaries and then optimized the desulfurization efficiency and operating costs while considering uncertainty errors. The fuzzy model employed max-min aggregation to optimize the degree of satisfaction on a scale from 0 (unsatisfied) to 1 (satisfied). Optimal conditions for gasoline UAOD were found at 445.43 W ultrasonic power, 4.74 min irradiation time, and 6.73 mL oxidant, resulting in a 66.79 % satisfaction level. This yielded a 78.64 % desulfurization efficiency (YA) at an operating cost of 13.49 USD/L. Compared to existing literature, gasoline desulfurization was less efficient and less costly. The solutions provided by MOFO demonstrate not only economic viability through decreased overall operating costs and simplified process conditions, but also offer valuable insights for optimizing prospective future industrial-scale UAOD processes.

A Phase I/II Investigation of Safety and Efficacy of Nivolumab and nab-Sirolimus in Patients With a Variety of Tumors With Genetic Mutations in the mTOR Pathway.

BACKGROUND/AIM: Advanced sarcoma has a poor prognosis. Dysregulation of the mammalian target of rapamycin (mTOR) occurs in various types of cancer. We aimed to determine the safety and efficacy of mTOR inhibitor nab-sirolimus when combined with the immune checkpoint inhibitor nivolumab. PATIENTS AND METHODS: Previously treated patients ≥18 years with confirmed diagnosis of advanced sarcoma or tumor with mutations in the mTOR pathway were treated with 3 mg/kg nivolumab intravenously every 3 weeks; escalating doses of nab-sirolimus at 56, 75 or 100 mg/m2 were administered intravenously on days 8 and 15 beginning in cycle 2. The primary aim was to determine the maximum-tolerated dose; we also determined disease control, objective response, progression-free survival, overall survival, and correlation between response using Immune-related Response Evaluation Criteria for Solid Tumors (irRECIST) versus RECIST v1.1. RESULTS: The maximum-tolerated dose was 100 mg/m2 There were two patients with partial response, 12 with stable disease and 11 with progressive disease. Median progression-free and overall survival were 12 and 47 weeks, respectively. The best responders (partial responses) were patients with undifferentiated pleomorphic sarcoma with loss of phosphatase and tensin homolog deleted on chromosome 10 (PTEN), tuberous sclerosis complex 2 (TSC2) mutation and estrogen receptor-positive leiomyosarcoma. Treatment-related adverse events of grade 3 or more included thrombocytopenia, oral mucositis, rash, hyperlipidemia and increased serum alanine aminotransferase. CONCLUSION: The data indicate that (i) treatment with nivolumab plus nab-sirolimus is safe with no unexpected adverse events; (ii) treatment outcome parameters were not improved by combining nivolumab with nab-sirolimus; and (iii) best responders were patients with undifferentiated pleomorphic sarcoma with PTEN loss and TSC2 mutation and estrogen receptor-positive leiomyosarcoma. Future direction in sarcoma research with nab-sirolimus will be biomarker-based (TSC1/2/mTOR, tumor mutational burden/mismatch repair deficiency etc.).

Comparing Perioperative Outcomes of Uterine Artery Embolization and Hysterectomy in Insurer and Demographically Diverse Populations: A Retrospective, Multi-Center Database Study.

INTRODUCTION: Past studies comparing perioperative outcomes of hysterectomy (HYST) and uterine artery embolization (UAE) do not control for demographically and insurer diverse populations. This study sought to identify the 30­day readmission, 15­day complication, and minimum 1­year surveillance reintervention rates of diverse, propensity matched patients undergoing UAE or HYST for uterine leiomyoma. METHODS: Adults from the New York's Statewide Planning and Research Cooperative System (SPARCS) database 2009­2013 who underwent HYST or UAE for uterine leiomyoma were retrospectively reviewed and 1:1 propensity matched. Univariate analysis compared demographics, complications, readmissions, and reintervention rates. Binary logistic and linear regression models identified independent predictors of outcomes. RESULTS: A total of 682 patients were identified, where the number (n) of patients in each cohort was n=341, HYST, and n=341, UAE. Significance levels are shown with p values. No significant differences were identified between HYST and UAE demographics, complication (2.60% HYST vs 2.90% UAE, p=0.816) or readmission rates (3.20% HYST vs 3.80% UAE, p=0.678); 0.30% of UAE patients had a reintervention UAE and 2.90% of UAE patients had reintervention hysterectomy. HYST patients had a significantly longer average length of stay (2.59 days HYST vs 1.63 days UAE, p<0.001). The Deyo-Charlson (Deyo) comorbidity score positively predicted any complication with odds ratio=34.262, 95% confidence interval [4.938, 237.725], and p<0.001, but did not predict readmissions. CONCLUSION: HYST patients had significantly longer hospital stays. UAE and HYST had comparable readmission and complication rates. The Deyo comorbidity score was a significant predictor of any complication. This study supports the safety and efficacy of UAE when compared to HYST in demographic and insurer diverse populations.

Electrospun Cadmium Selenide Nanoparticles-Loaded Cellulose Acetate Fibers for Solar Thermal Application.

Solar thermal techniques provide a promising method for the direct conversion of solar energy to thermal energy for applications, such as water desalination. To effectively realize the optimal potential of solar thermal conversion, it is desirable to construct an assembly with localized heating. Specifically, photoactive semiconducting nanoparticles, when utilized as independent light absorbers, have successfully demonstrated the ability to increase solar vapor efficiency. Additionally, bio-based fibers have shown low thermal conductive photocorrosion. In this work, cellulose acetate (CA) fibers were loaded with cadmium selenide (CdSe) nanoparticles to be employed for solar thermal conversion and then subsequently evaluated for both their resulting morphology and conversion potential and efficiency. Electrospinning was employed to fabricate the CdSe-loaded CA fibers by adjusting the CA/CdSe ratio for increased solar conversion efficiency. The microstructural and chemical composition of the CdSe-loaded CA fibers were characterized. Additionally, the optical sunlight absorption performance was evaluated, and it was demonstrated that the CdSe nanoparticles-loaded CA fibers have the potential to significantly improve solar energy absorption. The photothermal conversion under 1 sun (100 mW/cm2) demonstrated that the CdSe nanoparticles could increase the temperature up to 43 °C. The CdSe-loaded CA fibers were shown as a feasible and promising hybrid material for achieving efficient solar thermal conversion.